A peptide injection runs on five pieces of hardware: a reconstituted vial, a syringe, a needle, alcohol swabs and a sharps container. Only the syringe carries a specification this platform can source, and that specification is arithmetic rather than a recommendation.
That split runs through the whole page. The U-100 unit scale is definitional, tesamorelin's approved label fixes a real volume at a real concentration, and everything else on the table — gauge, length, adapter, swab, container — is convention that has never been written into a label or measured in a trial. Where a figure exists it is quoted; where none exists the row says so. The volume itself is settled upstream with the peptide dosing calculator and the reconstitution calculator, the mixing step in reconstituting peptides step by step, and the procedure in how to inject peptides.
What equipment does a peptide injection actually require?
The inventory is short, and it divides on one question: whether the dose is fixed by a manufacturer or calculated by the person holding the vial. A reconstituted research vial requires a syringe, a needle, swabs and a sharps container because the volume is variable and somebody has to measure it; bremelanotide's approved product requires none of them, because VYLEESI is a 1.75 mg in 0.3 mL autoinjector with no needle choice and no volume decision at all. Everything difficult about equipment lives in the first case.
Reconstituted vial and syringe | Fixed-dose autoinjector | |
|---|---|---|
Worked example | Tesamorelin 11.6 mg in 1.3 mL, 8 mg/mL | Bremelanotide 1.75 mg in 0.3 mL |
Who sets the volume | You do, from concentration and dose | The manufacturer, before it ships |
Syringe choice | Barrel size must match the volume | None |
Needle choice | Not sourced — convention only | None |
Dose-reading error possible | Yes — the barrel is read by a human | No |
Entries into the container | Seven over seven days on tesamorelin's label | One, then discarded |
Sharps generated | One syringe per dose, plus transfer needles | One device |
Regulatory status of the presentation | Research vial, unapproved | FDA-approved 2019, premenopausal HSDD |
The comparison is not an argument for one over the other, since almost nothing on this market is available as an approved device. It is a map of where error can enter. An autoinjector removes the barrel-reading step, the needle question and the multi-entry problem simultaneously, which tells you that those three are the places a vial-and-syringe setup can go wrong. Compound background for the approved case sits in PT-141 and bremelanotide science.
What does a U-100 insulin syringe actually measure?
Volume, not peptide. Units on a U-100 insulin syringe are volume markings: U-100 means 100 units per millilitre, so one unit is 0.01 mL, and that relationship never changes regardless of what is in the barrel. A 1 mL barrel is marked to 100 units, a 0.5 mL barrel to 50 units and a 0.3 mL barrel to 30 units. To convert directly, units equal the dose in milligrams divided by the concentration in mg/mL, multiplied by 100.
Worked example — tesamorelin's labelled daily dose in units
Input | Value | Source |
|---|---|---|
Vial | 11.6 mg, multi-dose | Approved label (EGRIFTA WR, BLA 022505) |
Diluent | 1.3 mL bacteriostatic water | Approved label |
Concentration after mixing | 8 mg/mL | Approved label |
Daily dose | 1.28 mg | Approved label |
Volume | 1.28 ÷ 8 = 0.16 mL | Arithmetic |
Reading on a U-100 barrel | 0.16 × 100 = 16 units | Arithmetic |
That is an example of the conversion, not a recommendation, and it holds only for the labelled presentation it comes from. Change the diluent volume and every figure below it changes with it. One term stays separate throughout: a unit on an insulin syringe is not an International Unit. IU measures biological activity and is used for compounds such as hCG and oxytocin, whose trials have run intranasal dosing up to 48 IU per day. The two abbreviations look identical in a forum post and mean unrelated things.
Run your own figures through the tesamorelin calculator and the reconstitution calculator, and see how to calculate peptide doses for the full arithmetic including the unit traps.
Which barrel should the dose land on?
The barrel is the one equipment choice with a measurable consequence, and the consequence is resolution. A dose that lands at 1.7 units on any barrel cannot be read accurately, and the fix is upstream in the diluent volume rather than in a steadier hand: the same 2 mL of diluent produces 2.5 mg/mL in a 5 mg vial, 5 mg/mL in a 10 mg vial and 15 mg/mL in a 30 mg vial, putting a 250 microgram dose at 10 units, 5 units or 1.7 units respectively.
Vial label | Diluent | Concentration | Volume for 250 mcg | U-100 units |
|---|---|---|---|---|
5 mg | 2 mL | 2.5 mg/mL | 0.10 mL | 10 units |
10 mg | 2 mL | 5 mg/mL | 0.05 mL | 5 units |
30 mg | 2 mL | 15 mg/mL | 0.017 mL | 1.7 units — not measurable |
Reconstituting that same 30 mg vial with 6 mL returns 5 mg/mL and puts the dose back at 5 units. Diluent volume exists to be chosen, and choosing it so a dose lands on readable graduations is a legitimate reason to depart from whatever volume a protocol specifies. That decision belongs before the vial is mixed, not at the point of injection.
The same pressure runs the other way at approved-label doses. At 5 mg/mL, semaglutide's 0.25 mg starting amount is 5 units, its 2.4 mg maintenance amount is 48 units, and the 7.2 mg dose approved in March 2026 is 144 units — more than a 1 mL barrel holds. A concentration chosen for the first week of an escalation does not survive to the end of it, which is an equipment consequence of a titration schedule. The semaglutide calculator and the tirzepatide calculator handle the compound-specific versions.
What does this platform publish about needle gauge, length and angle?
Nothing, and the reason is worth stating rather than filling. No approved peptide label in this fact base specifies a needle gauge or length for a self-administered research vial, and no trial here has compared angles or pinch technique, so every gauge, length and angle figure in circulation is convention rather than measurement — Peptigrity publishes none of them. What can be said is definitional: gauge runs inversely to bore width, so a higher number is a thinner needle.
Parameter | What it is claimed to control | Provenance |
|---|---|---|
Barrel size | Whether the volume lands on readable graduations | Arithmetic — your concentration and dose |
Unit scale | U-100: 100 units = 1 mL, 1 unit = 0.01 mL | Definitional |
Labelled volume example | 1.28 mg ÷ 8 mg/mL = 0.16 mL = 16 units | Approved label (EGRIFTA WR, BLA 022505) |
Gauge | Bore width; a higher number is a thinner needle | Not sourced — convention only |
Length | Reaching subcutaneous tissue rather than muscle | Not sourced — convention only |
Angle | Keeping the tip in subcutaneous tissue | Not sourced — no comparative trial located |
Pinch technique | Lifting fat away from the muscle beneath | Not sourced — a geometric claim, not a measured one |
Fixed-dose alternative | Removes the choice entirely | Approved label — bremelanotide, 1.75 mg in 0.3 mL |
Two things follow that matter more than a number would. A gauge figure with no source behind it is not made safer by being specific, and a reader who receives one should ask where it came from rather than which one to buy. And the angle is a means to a depth rather than a target in itself — a shorter needle into a site with tissue depth and a longer needle into a lifted fold can put the tip in the same place, which is why the two parameters cannot be specified independently by anyone who has not measured either. Technique sits in how to inject peptides, and the route argument in subcutaneous versus intramuscular injection.
Which accessories carry a specification, and which do not?
One of them does, and it is not the one people ask about. Bacteriostatic water is named in an approved label at a stated volume — 1.3 mL into an 11.6 mg tesamorelin vial — while vial adapters, filter needles, swab types and container specifications appear in no label and no trial in this fact base, so this platform publishes no specification for any of them. They may be sensible; they are not sourced, and the difference is what the table records.
Accessory | What it is used for | Provenance |
|---|---|---|
Bacteriostatic water | Diluent permitting repeated entry over days | Approved label — 1.3 mL, tesamorelin |
Alcohol swabs | Decontaminating the stopper and the skin | Cluster practice — at least two, allowed to air dry; no type, strength or contact time sourced |
Vial adapter | Transferring diluent without a needle through the stopper | Not sourced — no label or trial here specifies one |
Filter needle | Removing particulate during withdrawal | Not sourced |
Sharps container | Immediate disposal of the used needle | Requirement, not specification — in place before the first wrapper opens; container standards are set locally |
Second syringe for the transfer | Keeping the injection needle unblunted and sterile | Cluster practice — a needle through a rubber stopper is no longer sterile |
Vial label and date | Making a concentration and an in-use period knowable | Approved label implies it — tesamorelin: discard after 7 days |
The swab row is the one most often over-specified elsewhere. What the cluster states is procedural rather than numeric: swab the stopper, swab the site, and let the alcohol air dry rather than wiping it, because injecting through wet alcohol stings and the swab has not done its job until it is dry. No percentage, no timing, no brand — none of that is sourceable here. The diluent choice itself is argued in full in bacteriostatic versus sterile water.
What does a multi-dose vial require that a single-dose vial does not?
Repeated entry, and a diluent that anticipates it. Tesamorelin's presentation history makes the distinction concrete: EGRIFTA SV was a 2 mg single-dose vial reconstituted with 0.5 mL of diluent, and EGRIFTA WR is an 11.6 mg multi-dose vial reconstituted with 1.3 mL of bacteriostatic water to 8 mg/mL, giving seven doses and discarded after seven days. One vial is entered once; the other is entered seven times, and the diluent instruction changed with the presentation.
EGRIFTA (original) | EGRIFTA SV | EGRIFTA WR (current) | |
|---|---|---|---|
Vial | 1 mg and 2 mg | 2 mg, single-dose | 11.6 mg, multi-dose |
Reconstitution | — | 0.5 mL diluent | 1.3 mL bacteriostatic water (8 mg/mL) |
Entries per vial | — | One | Seven, across seven days |
Equipment consequence | — | One syringe, one sharp | Seven syringes, seven sharps, one stopper |
In-use period | — | — | Discard after 7 days |
The change came through supplement SUPPL-20 in March 2025, not through a new approval, and it also lowered the daily dose from 1.4 mg to 1.28 mg. Anyone working from older guidance is therefore working from the wrong vial size, the wrong diluent volume and the wrong dose at once, which is an equipment problem before it is a dosing problem.
The practical consequence for hardware is the sharps arithmetic. Seven doses across seven days is seven syringes and seven punctures of one stopper, so the container has to be sized for a week rather than for a dose, and the stopper has to survive seven entries. Disposal at that volume is covered in how to dispose of peptide syringes and sharps safely. Compound background sits in tesamorelin science and market figures on the tesamorelin compound page.
Why does better equipment not fix a dosing error?
Because the two largest sources of dosing error are fixed before the hardware is unwrapped. Fill variance and salt form are set at manufacture, and independent testing on this platform records tirzepatide vials running +2.6% to +26.7% against label, one tesamorelin sample at +23.6%, PT-141 at −3.3% to +16.3% and one IGF-1 LR3 sample at +72% over label — none of which any syringe, needle or adapter detects or corrects. A perfect 16-unit draw delivers whatever mass the vial actually contained.
That is the honest limit on what an equipment article can promise. Hardware controls the accuracy of the measurement, not the accuracy of the thing being measured, and a reader optimising gauge while ignoring net content is optimising the smaller variable by a wide margin. The quantity question is settled on a certificate rather than on a bench, and it is set out in why 10 mg isn't 10 mg and TFA versus acetate salt forms.
The second limit is chemical rather than quantitative. What is in the barrel is also whatever storage has made of it, and the degradation routes that matter are invisible to a purity certificate — covered in how to store peptides.
Which equipment errors actually cause harm?
The errors split by consequence rather than by item. Sterility failures put non-sterile material into tissue and have no later step that catches them, resolution failures deliver an amount nobody intended, and disposal failures injure somebody who was not part of the decision. Only the last of those three can harm a person other than the one holding the syringe, which is why it is the one with the least room for judgement.
Reusing the transfer needle for the injection. A needle that has passed through a rubber stopper is blunted and no longer sterile. Use a fresh sterile syringe and needle.
Choosing a barrel the dose cannot be read on. A 1.7-unit draw is not a measurement. Change the diluent volume before mixing, not the technique after.
Estimating between graduations. If the dose does not land on a mark, the concentration is wrong for the syringe you own.
Treating a unit as an International Unit. They measure different things; IU is biological activity, a syringe unit is 0.01 mL.
Buying a gauge because a forum specified one. No label here specifies a gauge, so a confident figure is confident about nothing.
Recapping a used needle. Recapping is the specific action behind most needlestick injuries in domestic settings. Uncapped, straight into the container.
Starting without the sharps container on the surface. The moment you need it is not the moment to go looking for it.
Using a single-dose presentation as a multi-dose vial. Repeated entry is what a preservative exists for, and a vial reconstituted without one was not designed for it.
Working from guidance written for an older presentation. Tesamorelin's move to the 11.6 mg vial in March 2025 changed the diluent volume, the concentration and the dose together.
Expecting hardware to correct a fill error. A +26.7% overage arrives in the vial and leaves in the syringe.
How do you check the equipment before you open anything?
Eight checks run before the first wrapper is opened, and every one of them is free at that point and expensive afterwards. Four concern the arithmetic — barrel size, the unit figure, the unit-versus-IU question and the vial's written concentration — and four concern the hardware itself, including whether a second syringe is on the surface and whether the sharps container is already there. None requires equipment beyond what is already in front of you.
Check | What it confirms | How | Red flag |
|---|---|---|---|
Barrel size against the calculated volume | The dose lands on readable graduations | Compare your unit figure with the barrel's scale | A dose landing near 1.7 units on any barrel |
The unit conversion recalculated | The arithmetic multiplied by 100 rather than dividing | mg ÷ mg/mL × 100 | A volume that looks a hundredfold wrong |
Unit versus International Unit | The right quantity is being read off the barrel | Check which one the protocol meant | An IU figure entered as syringe units |
Sterile packaging intact | The syringe has not been opened before | Look before unwrapping | A loose or previously opened wrapper |
A second syringe for the injection | The injection needle has not been through a stopper | Count the wrappers before starting | One syringe on the surface doing two jobs |
Sharps container present and closable | Disposal is possible at the moment it is needed | Place it before the first wrapper opens | Going to look for it after the injection |
Concentration and date written on the vial | The volume figure can be derived at all | Read the vial rather than the protocol | A vial carrying neither |
Presentation matched to the guidance | Single-dose and multi-dose are not interchangeable | Match the diluent volume to the vial in front of you | Guidance written for EGRIFTA SV's 2 mg vial |
Two of those rows are inherited rather than performed here. The concentration and the date were written at reconstitution, and if they are missing the equipment cannot recover them — the vial goes back to reconstituting peptides step by step. What a certificate can and cannot establish about injectable material is a separate question again, covered in peptide sterility testing under USP 71.
Which equipment claims survive the evidence?
Three of these nine claims are supported and all three are arithmetic or label text. The U-100 conversion, the labelled 16-unit volume and the multi-dose diluent instruction hold; every needle specification fails for want of a source rather than for being wrong. Untested and false are different verdicts, and the table keeps them apart, because a convention that has never been measured may still be sensible while a claim contradicted by a label is not.
Claim | Evidence | Verdict |
|---|---|---|
One unit on a U-100 syringe is 0.01 mL | Definitional — 100 units per mL | Correct |
Tesamorelin's labelled dose is 16 units | 1.28 mg ÷ 8 mg/mL = 0.16 mL | Correct — approved label plus arithmetic |
A multi-dose vial needs a preserved diluent | EGRIFTA WR: 1.3 mL bacteriostatic water, 7 doses, 7 days | Correct — labelled |
A specific needle gauge is required | No approved label here specifies one | Not sourced |
A specific needle length is required | No source located | Not sourced |
A specific injection angle is required | No comparative trial located | Convention only |
A vial adapter is necessary equipment | No label or trial here specifies one | Not sourced |
The transfer needle can be reused for the injection | Blunted and no longer sterile after a stopper | False |
Better equipment compensates for a mislabelled vial | Fill variance to +72% is fixed at manufacture | False |
What do 11,852 independent lab tests say about what goes in the syringe?
Equipment decides how material enters tissue and nothing about what the material is. Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026), and trust scores weight community reviews and independently verified HPLC purity equally at 50% each — and on the compounds used above, identity is rarely the failure while quantity frequently is. A syringe reads volume perfectly and tells you nothing about mass.
Compound | Purity Index | Tests · shops | Quantity finding |
|---|---|---|---|
Tirzepatide | 99.75% average HPLC | 930 tests, 227 shops selling | +2.6% to +26.7%; vials labelled 10–65 mg testing 10.71 to 68.1 mg |
Tesamorelin | 99.41% average HPLC | 497 tests, 227 verified vendors | One sample +23.6% above labelled quantity |
PT-141 | 99.70% average HPLC | 242 tests, 225 verified shops | −3.3% to +16.3% |
IGF-1 LR3 | 98.51% average HPLC | 125 tests, 220 verified shops | +1% to +72%, individual results 94.29% to 99.90% |
Tesamorelin price data shows 60 shops in stock, a median of $7.00/mg and a lowest tracked price of $3.50/mg on a 20 mg vial, across 73 comparable offers ranging to $22.00/mg (verified 8 August 2026). Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing. To turn a per-milligram price into a per-dose cost, use the cost-per-dose calculator.
Those certificates are ones vendors chose to publish, which is a selection-biased sample rather than a random survey of the market, and it remains the largest analytical dataset available. Individual results with the testing laboratory named sit in the lab test database, and per-compound averages in the Purity Index.
The trial that would settle this
Every needle specification on this market is convention, and the study that would replace one with a measurement is small and cheap. The trial that would settle peptide injection equipment randomises gauge and length against each other on a compound with a known injection-site reaction rate, and counts reactions and dose-delivery accuracy — because that is the only endpoint on which a needle choice could plausibly differ. Nothing about the design is demanding. It has never been run, which is why this page publishes no figure.
Element | Requirement | Why it is the gap |
|---|---|---|
Design | Randomised, within-patient, assessor-blinded | Gauge and length guidance is convention, not measurement |
Arms | Gauge against gauge, length against length | No approved label here specifies either |
Primary endpoint | Injection-site reaction rate and delivered volume | Site reactions are already measured on labels |
Compound | A labelled daily subcutaneous peptide | Tesamorelin: 1.28 mg daily, 16 units, 7 doses per vial |
Secondary arms | Vial adapter versus direct stopper entry; angle and pinch | Not sourced anywhere — pure convention |
Co-primary | Delivered mass against labelled mass | Fill variance runs to +26.7% and to +72% on IGF-1 LR3 |
Closest existing evidence | The EGRIFTA WR reconstitution instruction | A volume instruction, not an equipment comparison |
Frequently Asked Questions
What size syringe do I need for a peptide injection?
Whichever one puts your calculated volume on readable graduations. A 1 mL U-100 barrel is marked to 100 units, a 0.5 mL barrel to 50 and a 0.3 mL barrel to 30, and one unit is 0.01 mL on all of them. If the dose lands below a couple of units, change the diluent volume before mixing rather than the syringe afterwards.
What needle gauge should I use?
Peptigrity does not publish one, because no approved peptide label in this fact base specifies a gauge for a self-administered research vial. Gauge runs inversely to bore width, so a higher number is a thinner needle, and that relationship is definitional rather than a recommendation. Anything more specific than that is convention, wherever you read it.
Do I need a vial adapter?
No label or trial in this fact base specifies one, so this platform publishes no answer either way. What the cluster does state is that a needle pushed through a rubber stopper is blunted and no longer sterile, which is why the injection uses a fresh syringe and needle rather than the one used for the diluent transfer.
Is a unit on an insulin syringe the same as an International Unit?
No, and confusing them is a real dosing error. A syringe unit is a volume marking equal to 0.01 mL on a U-100 barrel. An International Unit measures biological activity and is used for compounds such as hCG and oxytocin, whose trials have run intranasal dosing up to 48 IU per day. The abbreviations look alike and mean unrelated things.
Can I reuse a syringe or needle?
The cluster's position is no, on two grounds that apply together. A needle that has already passed through a rubber stopper is blunted and no longer sterile, and a used sharp belongs in the container rather than back on the surface. Recapping to reuse is the specific action behind most needlestick injuries in domestic settings.
Does better equipment make an inaccurate vial safer?
No. Fill variance and salt form are fixed at manufacture, and independent testing here records tirzepatide at +2.6% to +26.7% against label and one IGF-1 LR3 sample at +72%. A syringe measures volume, not mass, so a perfectly read draw from an overfilled vial delivers an overdose with no visible error anywhere in the procedure.
Where equipment ends and the vial's contents begin
Equipment settles two questions and no others: whether the volume you intended is the volume that leaves the barrel, and whether the sharp ends up somewhere safe. It does not settle how many milligrams were in the vial, whether the molecule survived storage, or whether any human study supports the amount you calculated. On this page the sourced figures are the U-100 conversion, tesamorelin's 16 units and the multi-dose diluent instruction; the gauge, the length, the angle and the adapter are marked unsourced because they are.
Browse the growth hormone peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the tesamorelin calculator alongside the reconstitution calculator, and settle the arithmetic in how to calculate peptide doses. Disposal is covered in how to dispose of peptide syringes and sharps safely. Compare shops through independent lab tests and community-verified shop reviews.
This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
